Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Capital Expenditures (2016 - 2024)

NovaBay Pharmaceuticals (NBY) has disclosed Capital Expenditures for 14 consecutive years, with $4000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Capital Expenditures rose 33.33% to $4000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was $4000.0, a 20.0% decrease, with the full-year FY2024 number at $6000.0, down 68.42% from a year prior.
  • Capital Expenditures was $4000.0 for Q4 2024 at NovaBay Pharmaceuticals, up from $2000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $80000.0 in Q3 2022 to a low of $1000.0 in Q3 2023.
  • A 5-year average of $14333.3 and a median of $8000.0 in 2021 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: soared 370.59% in 2022, then plummeted 98.75% in 2023.
  • NovaBay Pharmaceuticals' Capital Expenditures stood at $21000.0 in 2020, then tumbled by 61.9% to $8000.0 in 2021, then surged by 900.0% to $80000.0 in 2022, then plummeted by 96.25% to $3000.0 in 2023, then skyrocketed by 33.33% to $4000.0 in 2024.
  • Per Business Quant, the three most recent readings for NBY's Capital Expenditures are $4000.0 (Q4 2024), $2000.0 (Q1 2024), and $3000.0 (Q4 2023).